Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021
05 mai 2021 06h45 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Present Clinical Updates for SRF388 and SRF617
28 avr. 2021 16h05 HE
|
Surface Oncology, Inc.
SRF388 Phase 1 Update to be Presented at American Society for Clinical Oncology Annual Meeting Company to Hold Webcast to Review Data from Ongoing SRF388 and SRF617 Phase 1 Clinical Studies on...
Surface Oncology Expands Leadership Team with Key Executive Appointment and Promotions
27 avr. 2021 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Named a 2021 Best Places to Work Company by Boston Business Journal
19 avr. 2021 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Surface Oncology, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment,...
Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting
09 avr. 2021 07h53 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology’s SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer
30 mars 2021 16h30 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Present Preclinical Data for Lead Product Programs at the American Association for Cancer Research Annual Meeting
10 mars 2021 16h35 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020
09 mars 2021 07h01 HE
|
Surface Oncology, Inc.
New Collaboration with Merck Will Evaluate SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) --...
Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
09 mars 2021 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor...
Surface Oncology to Participate in Upcoming March Investor Conferences
24 févr. 2021 07h00 HE
|
Surface Oncology, Inc.
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation therapies targeting the tumor...